Retatrutide dosage: what the clinical trials tested

Retatrutide has no approved dosage, because it is not an approved medicine.4 What exists is the dosing its clinical trials used: once a week, starting at 2 mg and stepping up every four weeks to 4 mg, 9 mg or 12 mg.2 This page lays that out, with the results and side effects by dose. It does not recommend a dose.

Important. Lilly says retatrutide is available only to participants in its clinical trials, and calls it "an investigational molecule that cannot be legally sold or marketed for human use."2, 3 The FDA says it cannot be used in compounding, and urges people not to buy products sold "for research purposes", because their quality is unknown and they may be harmful.4

Retatrutide at a glance

What it isAn agonist of three hormone receptors: GIP, GLP-1 and glucagon1
DeveloperEli Lilly2
FDA statusNot approved for any condition4
How trials gave itInjection under the skin, once a week1
Starting dose in Phase 32 mg, increased every four weeks2
Doses studied in Phase 34 mg, 9 mg and 12 mg2
CompoundingNot permitted under US federal law4
Next stepLilly plans to submit to the FDA in the first quarter of 20273

Retatrutide dosing schedule used in the Phase 3 trials

In TRIUMPH-1, everyone started at 2 mg once a week and moved up every four weeks until reaching their assigned dose. The 4 mg group took one step. The 9 mg group went through 2, 4 and 6 mg. The 12 mg group went through 2, 4, 6 and 9 mg.2

Weekly dose by trial arm. Laid out from the escalation Lilly describes for TRIUMPH-1. This is what the trial did, not a schedule to follow.
Period4 mg arm9 mg arm12 mg arm
Weeks 1 to 42 mg2 mg2 mg
Weeks 5 to 84 mg4 mg4 mg
Weeks 9 to 124 mg6 mg6 mg
Weeks 13 to 164 mg9 mg9 mg
Week 17 onward4 mg9 mg12 mg

Starting low was deliberate. The earlier Phase 2 trial compared starting doses and found that beginning at 2 mg instead of 4 mg partly reduced stomach and bowel side effects.1

Phase 2 trial: doses and results

The Phase 2 trial enrolled 338 adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition. It was double-blind and placebo-controlled, and ran for 48 weeks.1

Phase 2: average change in body weight. "Combined" groups pool two starting doses.
Weekly doseStarting doseAt 24 weeksAt 48 weeks
1 mgNot stated−7.2%−8.7%
4 mg (combined)2 mg or 4 mg−12.9%−17.1%
8 mg (combined)2 mg or 4 mg−17.3%−22.8%
12 mg2 mg−17.5%−24.2%
PlaceboNone−1.6%−2.1%
Phase 2: share of participants reaching each level of weight loss at 48 weeks.
Weekly dose5% or more10% or more15% or more
4 mg92%75%60%
8 mg100%91%75%
12 mg100%93%83%
Placebo27%9%2%

Both tables are from the published abstract.1 We have read the abstract only, not the full paper.

Phase 3 TRIUMPH trials: results by dose

Phase 3: average change in body weight at 80 weeks, efficacy estimand. Company press releases, not yet peer-reviewed.
Weekly doseTRIUMPH-1TRIUMPH-2TRIUMPH-3
4 mg−19.0%−12.7%Not studied
9 mg−25.9%−19.1%−21.6%
12 mg−28.3%−20.8%−22.6%
Placebo−2.2%−4.0%−3.2%
  • TRIUMPH-1: 2,339 adults with obesity or overweight and at least one weight-related condition, without diabetes.2
  • TRIUMPH-2: 1,152 adults with type 2 diabetes and obesity or overweight. Average blood sugar (A1C) fell by 1.4 to 1.6 points on retatrutide and 0.2 on placebo, from a starting level of 7.7%.3
  • TRIUMPH-3: 1,949 adults with a BMI of 35 or more and established cardiovascular disease.3

The 104-week extension

In TRIUMPH-1, 532 participants who began with a BMI of 35 or more continued for another 24 weeks, with their dose raised to the highest they tolerated, 9 mg or 12 mg. At 104 weeks their average weight loss was 27.9% to 30.3%, depending on the group they started in.2

How to read these numbers

  • They are averages. Individual results varied in every group.
  • The headline figures assume people stayed on the drug. That is what "efficacy estimand" means. Counting everyone, whether or not they kept taking it, TRIUMPH-1 reported 17.6%, 23.7% and 25.0% for the three doses.2
  • The starting point was high. TRIUMPH-1 participants weighed 112.7 kg (248.5 lb) on average, with an average BMI of 40.2
  • Results were smaller in people with diabetes. Compare the TRIUMPH-2 column with TRIUMPH-1.
  • Phase 3 results come from press releases. Lilly says detailed results will be presented at medical meetings and published in peer-reviewed journals.3

Why a trial dose is not a dose for you

Trial participants had to meet entry criteria and took part in double-blind, placebo-controlled studies run by the developer.1 None of that applies to a vial bought online. The FDA says products sold for "research purposes" are of unknown quality.4

A dose that was tested under those conditions is a fact about the trial. It is not an instruction. There is no approved label, so there is no official dosage chart, starting dose or schedule for use outside a trial.

Side effects reported in the trials

In Phase 2, the most common side effects were stomach and bowel related, more frequent at higher doses, and mostly mild to moderate. Heart rate also rose with dose, peaking at 24 weeks and declining afterwards.1

TRIUMPH-1: share of participants reporting each event.
Event4 mg9 mg12 mgPlacebo
Nausea28.6%38.4%42.4%14.8%
Diarrhea25.2%34.1%32.0%13.5%
Constipation23.8%25.9%26.1%10.9%
Vomiting10.6%22.8%25.3%4.8%
Upper respiratory infection14.2%12.2%13.1%11.6%
Dysesthesia5.1%12.3%12.5%0.9%
Urinary tract infection7.5%8.8%8.4%5.3%

Dysesthesia means an abnormal, unpleasant sensation. Lilly reported that dysesthesia and urinary tract infections were generally mild to moderate and that most resolved during treatment.2

Share of participants who stopped treatment because of side effects.
Trial4 mg9 mg12 mgPlacebo
TRIUMPH-14.1%6.9%11.3%4.9%
TRIUMPH-23.8%11.6%7.7%4.9%
TRIUMPH-3Not studied9.8%13.5%4.8%

Sources for the two tables: Lilly's releases.2, 3 In TRIUMPH-3, Lilly also reported cardiovascular event rates, with hazard ratios of 0.82 and 1.12 on two measures and confidence intervals that both include 1.3

Reconstitution math by vial size

The table is arithmetic only, generated by the same tested code as our calculator. It is not product information and not dose advice.

Arithmetic examples only.
Vial + waterConcentrationUnits per 1 mgAmount in 10 units
5 mg + 1 mL5 mg/mL200.5 mg
5 mg + 2 mL2.5 mg/mL400.25 mg
5 mg + 3 mL1.67 mg/mL600.17 mg
10 mg + 1 mL10 mg/mL101 mg
10 mg + 2 mL5 mg/mL200.5 mg
10 mg + 3 mL3.33 mg/mL300.33 mg
12 mg + 1 mL12 mg/mL8.31.2 mg
12 mg + 2 mL6 mg/mL16.70.6 mg
12 mg + 3 mL4 mg/mL250.4 mg
20 mg + 1 mL20 mg/mL52 mg
20 mg + 2 mL10 mg/mL101 mg
20 mg + 3 mL6.67 mg/mL150.67 mg
30 mg + 1 mL30 mg/mL3.33 mg
30 mg + 2 mL15 mg/mL6.71.5 mg
30 mg + 3 mL10 mg/mL101 mg

Concentration is the vial amount divided by the water added. On a U-100 syringe, 1 mL is 100 units.5 More water means a weaker mix and more units for the same amount; it does not change how much is in the vial. Calculators by vial size: 5 mg, 10 mg, 12 mg, 20 mg, 30 mg.

Retatrutide units calculator

mg
mL
Dose unit choose one
Syringe size units it holds

Because there is no approved retatrutide product, there is no official instruction for how much liquid to use, and this page cannot give a storage time for a mixed vial. For the mixing steps and a chart for each vial size, see how to reconstitute retatrutide.

Measuring errors are a known risk

The FDA has received reports of adverse events, some needing hospital care, that may be linked to dosing errors with compounded injectable semaglutide. In some, patients measured and gave themselves the wrong amount; in others, clinicians miscalculated.4 Those reports concern a different drug, but the arithmetic is the same.

  • Units on a syringe measure liquid, not medication. See units are not milligrams.
  • To check an amount you have drawn, use the units to mg calculator.
  • The FDA says to use a new sterile needle and syringe for every dose, and generally recommends using multi-dose sterile vials within 28 days of first use.4

Where approval stands

  • Not approved. The FDA says retatrutide is not a component of any approved drug and has not been found safe and effective for any condition.4
  • Not available through compounding. The FDA states it cannot be used in compounding under federal law, and has sent warning letters to telehealth companies, ingredient distributors and outsourcing facilities over it.4
  • Submission planned. Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027.3
  • What the FDA recommends. Get a prescription from your doctor and fill it at a state-licensed pharmacy.4

Questions

What is the dosage of retatrutide?

There is no approved dosage, because retatrutide is not an approved medicine. In the Phase 3 trials it was given once a week at 4 mg, 9 mg or 12 mg, with every participant starting at 2 mg.

What is the retatrutide dosing schedule in the trials?

Once weekly, starting at 2 mg and stepping up every four weeks: to 4 mg, then 6 mg, then 9 mg, then 12 mg, stopping at the assigned dose.

What was the starting dose of retatrutide in trials?

2 mg once a week in the Phase 3 trials. The Phase 2 trial compared starting at 2 mg with starting at 4 mg and found fewer stomach and bowel side effects with 2 mg.

What was the highest dose of retatrutide tested?

12 mg once a week, in both the Phase 2 and Phase 3 trials.

Is there an official retatrutide dosage chart?

No. A dosage chart comes from an approved label, and retatrutide has none. The chart on this page shows what the trials did.

Is retatrutide FDA-approved?

No. The FDA says it has not been found safe and effective for any condition, and Lilly describes it as investigational.

How many units is 1 mg of retatrutide?

It depends on the concentration of the vial. At 10 mg/mL, 1 mg is 10 units on a U-100 syringe. At 5 mg/mL it is 20 units.

How do you reconstitute retatrutide?

There is no official instruction, because there is no approved product. The general technique is on our reconstitution page, and the arithmetic for common vial sizes is in the table on this page.

When could retatrutide be approved?

Lilly has said it plans to submit retatrutide to the FDA in the first quarter of 2027. A submission is not an approval.

Does this page tell me what dose to take?

No. It reports what published trials tested and shows arithmetic. It does not recommend a dose.

Sources

  1. Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial." New England Journal of Medicine, 2023;389(6):514-526. ClinicalTrials.gov NCT04881760. We read the abstract only. doi.org/10.1056/NEJMoa2301972 (opens in a new tab)
  2. Eli Lilly and Company, press release, 21 May 2026: topline results from TRIUMPH-1 (NCT05929066). Company release, not peer-reviewed. investor.lilly.com (opens in a new tab)
  3. Eli Lilly and Company, press release, 23 July 2026: topline results from TRIUMPH-2 and TRIUMPH-3. Company release, not peer-reviewed. investor.lilly.com (opens in a new tab)
  4. U.S. Food and Drug Administration, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss", content current as of 1 October 2026. fda.gov (opens in a new tab)
  5. Pennsylvania Patient Safety Authority, newsletter, June 2025: insulin syringes are marked in units, with 1 mL equal to 100 units. patientsafety.pa.gov (opens in a new tab)
  6. Formulas and test cases: how the calculator math works.